ATLANTA, Jan. 7, 2013 /PRNewswire/ -- As part of a process to completely integrate the patient's electronic medical record (EMR) with treatment planning activities, Elekta has introduced MOSAIQ® Evaluate*, a toolset that unites plan and dose review capabilities in a single software framework, MOSAIQ Oncology Information System (OIS). Uniting MOSAIQ and powerful treatment planning review capabilities streamlines planning activities inside the patient chart, reducing patient wait times and delays and improving efficiency and productivity in the department. Elekta recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MOSAIQ Evaluate.
"The development of MOSAIQ Evaluate establishes a new standard of oncology treatment planning management in a single software environment. Our belief is that clinical decision-making is improved when the radiotherapy team can access and review treatment and patient data from one source, MOSAIQ," says Todd Powell, Executive Vice President, Elekta Software. "It's the first step in a process in which we will steadily integrate advanced toolsets inside MOSAIQ, ultimately creating an advanced, comprehensive treatment planning solution inside the EMR."
With MOSAIQ Evaluate, the entire radiation oncology team can access and review treatment plans and patient data from the patient's chart, streamlining the radiotherapy workflow. It enables plan review from virtually any treatment planning system and for any treatment modality, in addition to comparison of multiple plans.
To support the multidisciplinary team, MOSAIQ Evaluate offers specific benefits for the radiation oncologist, the physicist and the dosimetrist. Radiation oncologists and physicists will now be able to review plans at their MOSAIQ workstation and view a "to-do" list of plans needing review. MOSAIQ Evaluate also enables the physicist to identify approved plan information side-by-side with all treatment fields, approve treatment fields directly from the Plan Worklist, and view imported DRR's alongside the treatment plan. With MOSAIQ Evaluate, dosimetrists will be able to use the Plan Worklist to identify approved plans, triggering the next step in the workflow.
To learn more, visit www.elekta.com/evaluate.
*MOSAIQ Evaluate is not available for sale or distribution in all markets. Please contact the local Elekta representative for details.
For further information, please contact:
Johan Andersson Melbi, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: email@example.com
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: firstname.lastname@example.org
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.